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Abstract
Background: During sexual transmission of HIV in women, the virus breaches the multi-layered CD4 negative stratified
squamous epithelial barrier of the vagina, to infect the sub-epithelial CD4 positive immune cells. However the mechanisms
by which HIV gains entry into the sub-epithelial zone is hitherto unknown. We have previously reported human mannose
receptor (hMR) as a CD4 independent receptor playing a role in HIV transmission on human spermatozoa. The current study
was undertaken to investigate the expression of hMR in vaginal epithelial cells, its HIV gp120 binding potential, affinity
constants and the induction of matrix metalloproteinases (MMPs) downstream of HIV gp120 binding to hMR.
Principal Findings: Human vaginal epithelial cells and the immortalized vaginal epithelial cell line Vk2/E6E7 were used in
this study. hMR mRNA and protein were expressed in vaginal epithelial cells and cell line, with a molecular weight of
155 kDa. HIV gp120 bound to vaginal proteins with high affinity, (Kd=1.260.2 nM for vaginal cells, 1.460.2 nM for cell line)
and the hMR antagonist mannan dose dependently inhibited this binding. Both HIV gp120 binding and hMR exhibited
identical patterns of localization in the epithelial cells by immunofluorescence. HIV gp120 bound to immunopurified hMR
and affinity constants were 2.960.4 nM and 3.260.6 nM for vaginal cells and Vk2/E6E7 cell line respectively. HIV gp120
induced an increase in MMP-9 mRNA expression and activity by zymography, which could be inhibited by an anti-hMR
antibody.
Conclusion: hMR expressed by vaginal epithelial cells has high affinity for HIV gp120 and this binding induces production of
MMPs. We propose that the induction of MMPs in response to HIV gp120 may lead to degradation of tight junction proteins
and the extracellular matrix proteins in the vaginal epithelium and basement membrane, leading to weakening of the
epithelial barrier; thereby facilitating transport of HIV across the vaginal epithelium.
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Introduction
The global HIV-1 epidemic is fuelled through sexual transmis-
sion with women accounting for more than half of the 33 million
individuals infected with the virus [1]. The lower female re-
productive tract, is the initial site of contact with semen containing
cell free and cell-associated virus that have been documented to
transmit infection in vivo (in macaque studies) [2–5]. Although HIV
can infect the vaginal, ectocervical and endocervical mucosa, the
relative contribution of each site to the establishment of infection is
not known. The columnar epithelium lining the transformation
zone of the endocervix is single layered and thought to be
vulnerable to infection [2]; while the stratified squamous epi-
thelium lining the ectocervix/vagina is multi-layered and is
believed to offer protection against pathogens when intact [6–8].
However, the greater surface area of the vagina/ectocervical wall
provides more potential access sites for HIV entry, particularly
when breaches occur in the epithelial-cell layer. This is of
importance in light of the observation that HIV transmission can
occur solely through the vagina in the absence of the endocervix
and the uterus [9,10]. Moreover, anatomically in the vagina, the
HIV infected cells include the intraepithelial langerhans cells, T
cells [11], as well as dendritic cells, macrophages and T cells that
are found in the sub-epithelium or lamina propria below the
stratified squamous epithelial layer [12]. While it is plausible that
the langerhans cells may extend their projections to the surface, to
directly sample HIV from the lumen; HIV must also breach
though the robust multilayered vaginal epithelial barrier (25–40
layer thick) to infect the deeply embedded CD4+ immune cells
[2,12]. Thus, any aberrations in the integrity of the epithelial
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the mechanisms by which HIV gains entry into the sub-epithelial
zone is hitherto unknown.
While the epithelial cells are refractory to HIV entry [11,13–
15]; the intact epithelial barrier is impermeable to particles above
30 nm diameter, with the HIV virus estimated to have a diameter
of ,80–100 nm [8]. However, studies have demonstrated that
HIV penetrates interstitially between epithelial cells of the
stratified squamous epithelium as early as 2 hr [3,6,14]. These
observations rule out the possibility of HIV being transmitted via
the classical replication based mechanisms. Although transcytosis
of HIV through the epithelial cells has been reported, the extent is
estimated to be very low [16]. Therefore, there must exist
alternative mechanisms by which HIV must be able to breach the
vaginal epithelial layer.
We and others have previously reported hMR as a CD4
independent receptor playing a role in HIV transmission in
different cell types including spermatozoa [17–19]. In human
astrocytes, HIV binds to hMR and activates MMPs, which in turn
degrade the extracellular matrix proteins [20]. In case of primary
genital epithelial cells, HIV has also been reported to decrease the
expression of tight junction proteins and increase the leakiness of
the epithelial layer towards HIV [21,22]. This led us to
hypothesize that hMR may exist on vaginal epithelial cells, which
might bind to HIV gp120 leading to production of MMPs,
facilitating the degradation of junctional proteins and/or the
extracellular matrix in general, thereby inducing a disruption of
the epithelial layer organization.
To the best of our knowledge, it is unknown whether human
vaginal epithelial cells express hMR that may bind HIV gp120
and induce MMP production. In the present study, we aimed to
investigate this hypothesis by studying the presence of hMR, its
HIV gp120 binding potential and its affinity constants, and finally
the ability of HIV gp120 to induce MMP production via hMR.
Methods
Human vaginal epithelial cell specimens
Ethics Statement. Vaginal epithelial cells from the lateral
vaginal wall, were obtained by swab method from women
attending the obstetrics and gynecology clinics at NIRRH after
written informed consent, and this study and protocol were
specifically approved by the ‘National Institute for Research in
Reproductive Health Institutional Ethics Committee for Human
Subjects’. Women were in the age group of 21–35years, and had
regular menstrual cycles (28–35 days). Purity of the vaginal
epithelial cells was confirmed by staining for intracellular cy-
tokeratins. Viability was assessed using trypan blue, and samples
with greater than 80% viability were included in the study. To test
for possible contamination of other cells in the vaginal pre-
parations, RT-PCR for markers specific for lymphocytes (CD3),
dendritic cells (CD11c) and macrophages (CD14) was performed
using RNA derived from pools of vaginal epithelial cells as
template.
Culture of human vaginal epithelial cell line - Vk2/E6E7
The cell line was obtained from American Type Culture
Collection, originally prepared by R. Fichorova (Fearing Research
Laboratory, Boston, MA). Cells were grown as described pre-
viously [23] in keratinocyte serum free medium (K-SFM)
supplemented with 0.1 ng/ml EGF, 50 ug/ml bovine pituitary
extract (Invitrogen, Carlsbad, CA) and 0.4 mM CaCl2 (Sigma, St.
Louis, MO), at 37uC and 5% CO2. Cells were split 1:3 at 60%
confluence. The Vk2/E6E7 cells express markers of terminal
differentiation (involucrine and cytokeratin 13) just as fully
differentiated vaginal cells on the surface of vaginal tissues [23].
This cell line represents a valid model that has been used by many
others to study HIV - epithelial interaction events [24–28].
HIV gp120 binding to vaginal proteins and competitive
inhibition by mannan
As a source of human vaginal proteins, human vagina protein
medley comprising SDS solubilized proteins from normal human
vagina was purchased from Clontech (CA, USA). Vk2/E6E7 cells
were lysed in protein extraction buffer M-Per reagent (Pierce,
Rockford, USA). The binding of gp120 to vaginal proteins was
tested as described earlier [19] with minor modifications. Briefly,
wells of an ELISA plate were coated overnight at 4uC, with 20 ug
of proteins in 100 ul of a 0.1 M carbonate buffer, pH 9.2. Wells
were washed in TBS (Tris Buffered Saline) and blocked in 0.3%
BSA prepared in TBS containing 0.1% Tween for 2 hr at room
temperature. Increasing concentrations of HIV gp120-IIIB HRP
conjugated (Immunodiagnostics, Woburn, Ma USA) (0.2 nM–
10 nM) were incubated overnight, followed by six TBS washes
containing 0.1% Tween-20. Binding was determined using the
substrate TMB/H2O2 and absorbance was read at 450 nm. Wells
coated with BSA (bovine serum albumin) or no vaginal proteins
served as the negative control. The hMR antagonist mannan
(1000 ng/ml to 50 mg/ml) (Sigma) or sucrose (unrelated carbo-
hydrate) was co-incubated with labeled HIV gp120 (100 ng/ml),
reacted with vaginal proteins and detected as above. Further, the
binding of HIV gp120 (100 ng/ml), was also studied in the
presence of increasing doses of the hMR blocking antibody (clone
19.6 BD Pharmingen, San Diego, CA, USA) or an isotype control
IgG, and the binding was quantified as described above.
hMR expression by RT-PCR and Western blotting
RNA was extracted from vaginal epithelial cells (n=22, pooled
in groups 3–5samples) or the Vk2/E6E7 cell line using the Qiagen
RNeasy mini kit, (Qiagen, CA, USA). DNase-treated RNA
samples were subjected to RT-PCR. RNA was reverse transcribed
to cDNA and amplified with the SuperScript One-Step RT-PCR
kit (Invitrogen). Briefly, the reaction mixture of 25 ml contained
0.4 mM each of forward and reverse primers, 200 mM dNTP mix
and 1 U SuperScript III RT/Platinum Taq enzyme mix. The
reverse transcription was carried out at 55uC for 30 min, followed
by denaturation at 94uC for 2 min. This was followed by 35 cycles
of amplification, each cycle comprising denaturation at 94uC for
15 s, annealing at 58uC for 30 s and extension at 68uC for 30 s.
cDNA was PCR amplified using hMR specific primers– FP: 59
TAC-ACA-AAC-TGG-GGG-AAA-GG 39 and RP 59 TGT-
TTG-AAT-CGT-TGC-TGG-AG 39 as described earlier [17].
The amplification conditions included denaturation at 94uC for
15 s, annealing at 58uC for 30 s, extension at 68uC for 30 s, with a
final extension at 68uC for 5 min. The PCR products were
sequenced with an automated fluorescence-based sequencer at the
core sequencing facility at the institute. Detection of the size of
vaginal hMR protein was performed by SDS-PAGE and western
blotting of human vaginal protein lysates and Vk2/E6E7 protein
lysates. Blots were probed with goat polyclonal anti-hMR serum
(1:1000) (kind gift from Dr. Stahl) as described earlier [17]. Blots
probed with normal goat serum served as a negative control.
HIV gp120 binding and hMR staining by direct
fluorescence
Smears of vaginal epithelial cells were processed for HIV gp120-
IIIB FITC (Immunodiagnostics) binding (n=30) and hMR
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Vk2/E6E7 cell line were grown in K-SFM on glass coverslips and
processed similarly. Images were obtained using the Zeiss LSM-
510 Meta confocal laser scanning microscope.
HIV gp120 binding to vaginal hMR
A capture ELISA was developed in the laboratory to study the
binding of HIV gp120 to hMR. Briefly, goat anti-hMR polyclonal
antibody (1:1000) in 0.1 M carbonate buffer pH 9.2, was
immobilized in wells of an ELISA plate, overnight at 4uC. The
wells were washed twice with TBS containing 0.1% Tween (wash
buffer), and non-specific binding was blocked using 1% BSA.
Human vaginal proteins or Vk2/E6E7 proteins (20 ug) were added
to the wells and incubated at 37uC for 1.5 hr, followed by three
washes. The ligand HIV gp120 HRP conjugated (100 ng/ml) was
added in the presence or absence of the hMR blocking antibody
(clone 19.6 BD Pharmingen, San Diego, CA, USA) and detected as
described above. Wells coated with normal goat serum and wells
containing no vaginal proteins served as controls in the experiment.
Affinity constants of hMR for HIV gp120
The affinity constants of HIV gp120 to hMR were determined by
competitive ELISA optimized in the laboratory. Briefly, 3.3 nM of
HIV gp120-IIIB (Immunodiagnostics) in 0.1 M carbonate buffer
pH 9.2, was immobilized in wells of an ELISA plate, overnight at
4uC. The wells were washed twice with TBS and vaginal proteins or
Vk2/E6E7 proteins (20 ug/well) were incubated at 37uC for 1.5 hr.
To determine the affinity constants, the vaginal or the cell line
proteins were mixed with increasing amounts of gp120 (0.083 nM to
40 nM) and then added to the wells. The wells were then washed to
remove unbound proteins, and incubated with anti-hMR polyclonal
antibody (1:1000) for 2 hr at 37uC to detect the amounts of hMR
bound to the immobilized gp120 in the wells. The wells were washed
again to remove the excess antibody and then detected using the
rabbit anti-goat HRPconjugated secondaryantibody (1:5000) (Dako,
Glostrup, Denmark). HRP assay was performed as described above
and the OD was read at 450 nm. The negative control comprised of
wells that had BSA in place of immobilized gp120; wells which did
not contain vaginal proteins served as an additional control.
Measurement of MMP mRNA levels and activity
For the experiments on MMPs and TIMPs, cells were seeded at
density of 1610‘6 cells/well in six well tissue culture plates (Fisher
Scientific, Hampton, NH) or 4610‘4 cells/well in 96 well plates.
Confluent Vk2/E6E7 cells were treated with HIV gp120 (0.083 nM to
83 nM). These concentrations were chosen based on the affinity
constants of hMR determined herein and have been reported to be
used by others in different cell types [29–32]. In some experiments in
96 well plates, along with HIV gp120 (83 nM), cells were coincubated
with hMR antibody clone 19.2 or isotype matched IgG. Cell
supernatants were collected after 24 hr and assayed for MMP activity
by zymography using 1 mg/ml gelatin as a substrate as described [33].
Briefly, samples were electrophoresed through a 10% polyacrylamide
gel containing 1 mg/ml gelatin. After electrophoresis, gelatin gels were
equilibrated for 30 min at room temperature with zymogram
renaturing buffer 22.7% Triton X-100 with gentle agitation.
Zymograms were incubated for 12 h at 37uC in zymogram developing
buffer 22 0 0m MN a C l ,5m MC a C l 2, 0.02% Brij 35, and 50 mM
Tris pH 7.5. Gels were stained with 0.5% Coomassie Blue at for 1 hr,
destained with methanol:glacial acetic acid:water (50:10:40) till clear
bands were obtained against a blue background. Bands corresponding
to MMP-9 and MMP-2 were identified based on their molecular
weight and were quantitated by densitometry (Syngene, Cambridge,
United Kingdom).
Cell lysates were used to measure MMPs at the mRNA level by
real time PCR. RNA was extracted as described above and reverse
transcribed to prepare cDNA using the Advantage RT-for-PCR kit
(Clontech, CA, USA). Briefly, 1 ug of RNA was heat denatured at
70uC for 2 min, and then reverse transcribed using MMLV reverse
transcriptase and 20 pmol random hexamers, 10 mM dNTPs, in a
20 ul reaction volume; at 42uC for 1 hr. Real time PCR was
performed, using TaqMan (Applied Biosystems, Foster City, CA)
gene expression primer and probe sets on the ABI Prism 7900HT
(Applied Biosystems). Briefly, a 20 ul reaction mixture contained
2 ul of cDNA, 16TaqMan primer probe mix diluted in TaqMan
universal PCR master mix and each reaction was set in duplicates.
Cycling was carried out at 50uC for 2 min, 95uC for 10 min, and 40
cycles of 95uC for 15 s with an annealing and extension at 60uC for
1 min. A no-template control (H2O control) was analyzed for each
master mix. All experiments were repeated in triplicates. Levels of
18S rRNA were used for normalization. All probes were FAM
labeled except 18S which was VIC labeled. The relative expression
ratios were calculated manually using Pfaffl method [34].
Data analysis and statistical methods
Dissociation constant Kd values were computed using Graph-
Pad
TM Prism software (San Diego, CA). Data were evaluated
using unpaired Students t-test. p,0.05 was accepted as statistically
significant.
Results
Binding of HIV gp120 to vaginal proteins and effect of
mannan on binding
The binding of HIV gp120 to vaginal proteins, was found to be
of high affinity and saturatable (Fig. 1a and b). The affinity of HIV
gp120 binding to human vaginal proteins was computed to be
1.260.2 nM and 1.4 nM60.2 nM for the Vk2/E6E7 cell line.
BSA at identical or 1006 concentrations did not demonstrate
gp120 binding.
Mannan (an hMR antagonist), dose dependently inhibited the
binding of HIV gp120 to vaginal proteins of either sources, while
sucrose (unrelated carbohydrate) had no effect. Mannan at doses
ranging from 0.1 mg/ml to 50 mg/ml significantly reduced HIV
gp120 binding to human vaginal protein lysates (Fig. 1c) and Vk2/
E6E7 lysates (Fig. 1d). At the highest concentration mannan
inhibited gp120 binding by almost 75%, indicating that HIV
gp120 potentially binds to hMR.
The hMR blocking antibody was found to inhibit the binding of
HIV gp120 to vaginal proteins (Fig. 1e), and Vk2/E6E7 proteins
(Fig. 1f) by almost 60%. An unrelated isotype matched IgG did not
influence the binding, thus demonstrating the specificity.
Expression of hMR in vaginal cells
The vaginal epithelial cells were collected by gentle scraping of
the lateral vaginal walls and were always observed under a
microscope for possibility of other contaminating cells. Most of our
preparations were free of any visible contamination; samples
where any contaminating cells were visible, were excluded from
the study. The purity was also evident by RT-PCR where RNA
isolated from 5 independent preparations (and also other pools)
did not show presence of transcripts for CD3, CD14 and CD11c
which are markers for lymphocytes, macrophages and dendritic
cells respectively (Fig. 2a). Bands of expected sizes were however
detected in RNA isolated from PBMCs (peripheral blood
mononuclear cells) that was used as a positive control. 18S rRNA
was detected in all the samples.
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cation of a product of expected size (201 bp) and sequence that
matched with 99% identity to macrophage hMR,w h e nR N A
from vaginal epithelial cells or Vk2/E6E7 cells was used as a
template (Fig. 2b). In western blots of human vaginal proteins or
Vk2/E6E7 cell lysates, probed with goat anti-hMR polyclonal
serum, a single band of ,155 kDa was detected. No bands were
observed when blots were probed with normal goat serum
(Fig. 2c).
Localization of HIV gp120 Binding and hMR expression in
vaginal cells
HIV gp120-IIIB FITC binding to human vaginal epithelial cells
is depicted in Figure 3a and 3e. The staining in vaginal epithelial
cells was found to be heterogeneous and of varying intensities. This
binding was specific as the fluorescence staining disappeared when
the cells were coincubated with excess of unlabeled gp120 (inset
Fig. 3a). In case of Vk2/E6E7 cell line, gp120 bound homo-
genously to all the cells (Fig. 3b and 3f), which was also displaced
by unlabeled protein (inset Fig. 3b).
hMR expression on human vaginal epithelial cells (Fig. 3c and
3g) and the cell line (Fig. 3d and 3h) exhibited identical patterns of
staining as observed for HIV gp120 binding. No staining was
observed when anti-IgG FITC antibody was used instead of anti-
hMR FITC antibody (inset Fig. 3c and 3d).
The heterogenous punctate staining pattern for HIV gp120
binding as well as hMR expression in vaginal epithelial cells was
observed across several samples (n=30 in each case); with a total
Figure 1. Binding of HIV gp120 to vaginal proteins and its inhibition by mannan or the hMR blocking antibody. Saturation isotherm of
HIV gp120 HRP conjugated binding at the indicated concentrations on the X axis to (a) vaginal protein lysates (Kd=1.260.2 nM) and (b) vaginal
epithelial cell line Vk2/E6E7 protein lysates (Kd=1.460.2 nM). Results are representative of three experiments. Inhibition of HIV gp120 binding using
mannan in (c) vaginal protein lysates or (d) Vk2/E6E7 protein lysates. Mannan or sucrose concentrations in ug/ml are plotted on a logarithimic scale.
Experiments were repeated in triplicates. Binding of HIV gp120 to (e) vaginal protein lysates or (f) Vk2/E6E7 protein lysates in the presence of
increasing concentrations of hMR blocking antibody or isotype matched IgG antibody. Results are mean 6 SE, n=3.
*Statistically significant (p,0.05)
when compared with cells treated with HIV gp120 in the absence of antibody.
doi:10.1371/journal.pone.0028014.g001
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the Vk2/E6E7 cell line were repeated in triplicates.
Binding of HIV gp120 to vaginal hMR
Wells coated with anti-hMR polyclonal antibody and incubated
with human vaginal proteins or Vk2/E6E7 lysates, exhibited an
almost forty fold higher binding of HIV gp120 as compared to
negative controls (normal goat serum or no vaginal protein
controls). This binding of HIV gp120 to immunopurified hMR
was specific, as this binding was reduced to levels comparable to
negative controls, in the presence of a neutralizing monoclonal
anti-hMR antibody (Fig. 4a).
Affinity constants of hMR for HIV gp120
To determine the affinity constant of hMR for HIV gp120, a
competition ELISA was utilized. In step 1, hMR from vaginal
proteins bound to immobilized gp120 in the well and represents
‘Total hMR binding’. Step 2 involved binding of vaginal proteins
with increasing amounts of free gp120 followed by its competition
with immobilized gp120. hMR not complexed with free gp120
would bind to the immobilized gp120 in the wells. In step 3 the
amount of hMR bound to the immobilized gp120 was estimated.
A concentration dependent reduction in hMR binding was
observed. To obtain the amounts of gp120 complexed to hMR
in step 2, the value from step 3 was subtracted from that observed
for Total hMR binding (step 1). These values (obtained at each
concentration) were used to compute the affinity constant (Fig. 4b
and 4c). HIV gp120 binding to hMR was found to be
concentration dependent and saturatable. The Kd value (dissoci-
ation constant) was computed to be 2.960.4 nM (Fig. 4b) from
human vaginal proteins and 3.260.6 nM (Fig. 4c) from Vk2/
E6E7 cell line.
HIV gp120 induces MMP-9 production
Treatment of Vk2/E6E7 cells with increasing concentrations of
HIV gp120, resulted in a dose dependent and significant increase
in the mRNA expression of MMP-9 but not MMP-2 (Fig. 5a). As
compared to untreated controls, the MMP-9 mRNA levels were
two fold higher, in the cells treated with 83 nM of HIV gp120.
Culture supernatants were assayed for MMP-9 and MMP-2
Figure 2. Expression of hMR in vaginal cells. (a) Purity of vaginal
epithelial cells: RT-PCR for lymphocyte marker CD3 (lane 2, 5 9),
macrophage/monocyte marker CD14 (lanes 3, 6, 10) and dendritic cell
marker CD11c (lanes 4, 7 and 11) using RNA isolated form PBMCs (lane
2, 3, 4), epithelial cells (lanes 5, 6, 7) and Vk2/E6E7 (lanes 9, 10, 11). Lanes
8 and 12 - positive control (18S rRNA) from vaginal epithelial cells and
Vk2/E6E7 cells respectively. Lane 1 is 100 bp ladder. (b) RT-PCR for hMR
mRNA: Lane 1: 100 bp DNA ladder. Lanes 2 and 6: Amplification of hMR
in RNA derived from vaginal epithelial cells and Vk2/E6E7 cells
respectively using hMR specific primers (201 bp product). Lanes 4
and 5: positive control (18S rRNA) from vaginal epithelial cells and Vk2/
E6E7 cells respectively. Lane 3: negative control (no template). (c)
Western blot for hMR protein: Lane 1: human vaginal protein lysate and
lane 2: Vk2/E6E7 protein lysate were probed with goat polyclonal anti-
hMR serum (1:1000) and HRP conjugated donkey anti-goat secondary
antibody (1:5000), and detected by chemiluminescence. Lane 3: human
vaginal protein lysate and lane 4: Vk2/E6E7 protein lysate were probed
with normal goat serum (negative controls) and detected as in lanes 1
and 2.
doi:10.1371/journal.pone.0028014.g002
Figure 3. Localization of HIV gp120 binding and hMR in vaginal epithelial cells. Vaginal epithelial cells (a and e) and Vk2/E6E7 cells (b and
f) incubated with FITC labeled HIV gp120 (green fluorescence) and counter stained with propidium iodide (red fluorescence). Vaginal epithelial cells (c
and g) and Vk2/E6E7 cells (d and h) probed with hMR antibody (green fluorescence) and counter stained with propidium iodide (red fluorescence).
Inset on (a) and (b) represents vaginal epithelial cells and Vk2/E6E7 cells respectively, incubated with excess unlabelled gp120. Inset on (c) and (d)
represents negative control (-ve), for vaginal epithelial cells and Vk2/E6E7 cells respectively labeled with IgG antibody FITC labeled. Images (a and c)
are at 4006magnification, (b and d) are at 6306magnification. (e–h): Images captured at 12606magnification and further digitally magnified.
doi:10.1371/journal.pone.0028014.g003
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to MMP-9 and MMP-2 respectively were obtained on zymograms
(Fig. 5c). As compared to the untreated controls, increasing doses
of HIV gp120 significantly increased the activity of MMP-9; the
activity of MMP-2 was unchanged (Fig. 5b). At 83 nM
concentration of HIV gp120, the activity of MMP-9 doubled as
compared to untreated controls.
To test if the increase in MMP-9 by HIV gp120, is mediated via
hMR, the Vk2/E6E7 cells were incubated with the neutralizing
monoclonal blocking antibody (clone 19.2) along with HIV gp120.
The anti-hMR antibody significantly inhibited the HIV gp120
mediated increase in MMP-9 mRNA expression (Fig. 5d) and
activity (Fig. 5e). This inhibition was specific because an isotype
specific mouse IgG did not affect the HIV gp120 mediated
increase in MMP-9 transcription and activity.
Discussion
The present study demonstrates that human vaginal epithelial
cells and the Vk2/E6E7 cell line interact with HIV gp120 via the
hMR. Mannose receptors on vaginal epithelial cells were found to
exhibit high affinity binding to HIV gp120, demonstrated
saturatable binding kinetics and were inhibited by the mannose
receptor antagonist mannan. Further, we demonstrate that
binding of HIV gp120 to hMR increases MMP-9 transcription
and activity in the Vk2/E6E7 cells. To the best of our knowledge,
this is the first report demonstrating the presence of hMR on
human vaginal epithelial cells, and its ability to bind to HIV gp120
leading to MMP production.
The sexual route of HIV transmission accounts for 70–80% of
the HIV epidemic with females being disproportionately affected
compared to males [1]; yet HIV transmission across the CD4
negative stratified squamous vaginal epithelium of the lower
female reproductive tract remains enigmatic. In women treated
with nanoxynol-9 which damages the vaginal epithelium, a higher
risk of HIV infection is reported [35]; micro-aberrations of the
vaginal epithelium due to physical insults or inflammation due to
STI infections is also known to increase the infectivity [2,6]. In a
recent study by Horbul et al, herpes simplex virus induced
disruption of the surface epithelium allowed direct access of HIV
to sub-mucosal CD4+ T cells [36]. Thus, the epithelial barrier
integrity appears to be a crucial determinant for HIV entry via the
sexual route. Studies have demonstrated that the normal vaginal
epithelium has limited permeability; the vaginal epithelial cells are
connected by tight junctions, adherens junctions and desmosomes
that form an intercellular seal to restrict paracellular diffusion of
molecules across the epithelial sheet [37]. These epithelial cells
(25–40 layer thick) rest on a basement membrane comprised of
extracellular matrix proteins which are secreted by the epithelial
cells [38]. Hence the incoming virus must traverse through several
layers of impervious vaginal epithelium and also breach the
basement membrane, before it can reach and infect the target
CD4+ immune cells in the sub-epithelium. The fact that HIV
particles have been detected interstitially between cells in several
layers of the stratified epithelium [7,14] and also in the lowermost
layer of cells of the vaginal epithelium that rests on the basement
membrane [7,11], suggests that there must exist a mechanism by
which the virus, would first affect the epithelial cells, and alter their
physiology, making them more permeable to eventually allow viral
entry and penetration into the sub-epithelial layers. Towards this
end, we hypothesized that there must exist some specific receptors
for HIV on the human vaginal epithelial cells, which when
activated would weaken the epithelial barrier, permitting viral
entry to sub-epithelial cells.
Firstly, we studied HIV gp120 binding to human vaginal cell
protein lysates and lysates from Vk2/E6E7 cells. HIV gp120
readily bound to proteins from both sources, and this binding was
saturatable and of high affinity with Kd values of 1.260.2 nM and
1.460.2 nM respectively. These results indicate that there exist
some high affinity receptors for gp120 on the vaginal epithelium.
Vaginal epithelial cells were found to be negative for the classical
CD4, CXCR4 and CCR5 receptors (unpublished data). Indeed
non-cannonical HIV receptors like syndecans [16] and gp340 [26]
have been reported to be present on human vaginal epithelial cells.
Beyond these, hMR is a non-cannonical receptor for HIV gp120
[17–19]. To test if hMR could be a putative HIV binding protein
in human vaginal cells, we tested the effect of the hMR antagonist
mannan on HIV gp120 binding. As reported earlier [17–19],
mannan inhibited the binding of HIV gp120 to vaginal proteins
leading us to speculate that HIV gp120 may bind to hMR. To test
this further, the binding of HIV gp120 was also tested in the
presence of an hMR antibody that is known to neutralize ligand
binding. This antibody also reduced gp120 binding to vaginal
proteins significantly suggesting that HIV gp120 does bind to
hMR in vaginal cells.
Figure 4. HIV gp120 binding to vaginal hMR and its affinity constants. (a) HIV gp120 binding and its inhibition to immunopurified hMR from
human vaginal proteins and Vk2/E6E7 proteins. Results are mean 6 SE, n=3. *Statistically significant (p,0.05) when compared with controls.
#Statistically significant (p,0.05) when compared with HIV gp120 treated cells. Saturation Isotherm of HIV gp120 binding to hMR immunopurified
from (b) human vaginal proteins and (c) Vk2/E6E7 proteins at concentrations indicated on the X axis. Affinity constants, Kd=2.960.4 nM and
Kd=3.260.6 nM for human vaginal proteins and Vk2/E6E7 proteins respectively. Results are a representative of three independent experiments.
doi:10.1371/journal.pone.0028014.g004
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cells has not been reported. In the present study, for the first time
we demonstrated that both hMR mRNA and protein are
expressed by vaginal cells and also in the epithelial cell line.
hMR transcripts were detected by RT-PCR in RNA isolated from
vaginal epithelial cells and also from the cell line. The transcript
detected in the squamous cells was not from any contaminating
lymphocytes, macrophages or dendritic cells indicating that the
squamous epithelial cells indeed transcribe hMR. In vaginal
squamous epithelial cells, we observed a heterogenous punctate
or speckled pattern of hMR staining by immunofluorescence, and
this pattern replicated when HIV gp120 was used as a probe.
hMR has been found to exist in equilibrium, in both monomeric
and dimeric forms [39,40]. It is possible that in the vaginal
epithelial cells too, hMR may exist in a multimeric form and may
appear as aggregates. However, such punctate pattern of staining
was not observed in cell lines, where both hMR and gp120 binding
appeared homogenous. At present it is difficult to explain the
reason for such differences in staining pattern; it is possible that in
vivo hMR may have already experienced its ligands, and may have
dimerized, which may not occur in case of the cell lines.
The observation that mannan inhibited HIV gp120 binding to
vaginal cells as well as the Vk2/E6E7 cell line, and hMR is
expressed by the same, prompted us to test if HIV gp120 binds to
hMR and determine its binding kinetics. Immunopurified hMR
from vaginal proteins of either source bound to gp120, and this
binding could be displaced by a blocking anti-hMR antibody.
The HIV gp120 binding to hMR was concentration dependent
and saturatable with a dissociation constant in the range of
2.960.4 nM for human vaginal proteins and 3.260.6 nM in the
case of Vk2/E6E7 cell line proteins; demonstrating it to be a high
affinity gp120 receptor. It is interesting to note that this affinity is
within the range reported for hMR from other cells [41,42].
However, this dissociation constant is lesser than that observed for
HIV gp120 binding to total vaginal proteins observed herein. This
is not surprising, as beyond hMR other non-cannonical HIV
receptors like syndecans and gp340 are also known to be present in
vaginal epithelial cells [16,26].
At present the concentrations of gp120 in the female
reproductive tract are not known. In vivo, gp120 exists in both
soluble forms and virion bound. Gp120 which is labile due to non-
covalent linkage with gp41, sheds spontaneously from the surface
Figure 5. Effect of HIV gp120 on MMP production. (a) Effect of increasing concentrations of HIV gp120 on mRNA expression of MMP-9 and
MMP-2 in Vk2/E6E7 cells. (b) Effect of increasing concentrations of HIV gp120 on MMP-9 and MMP-2 activity. (c) Representative zymograms of HIV
gp120 treated Vk2/E6E7 cells (upper panel); lane 1: untreated cells, lane 2: 0.083 nM of HIV gp120, lane 3: 0.83 nM of HIV gp120, lane 4: 83 nM of HIV
gp120. Lower panel represents effect of anti-hMR antibody on activity of MMP-9 and MMP-2; lane 1: Cells treated with HIV gp120 (83 nM), lane 2:
HIVgp120 (83 nM) + isotype IgG, lane 3: HIV gp120 (83 nM) + anti-hMR IgG, lane 4: untreated cells. (d) Effect of anti-hMR antibody on expression of
HIV gp120 induced MMP-9 mRNA. (e) Effect of anti-hMR antibody on MMP-9 activity. (a) and (d) values are mean 6 SE of relative expression
normalized to 18S rRNA from 3 independent experiments. (b) and (e) are mean 6 SE of MMP activity expressed as fold change over unstimulated
cells from 3 independent experiments. *Statistically significant (p,0.05) when compared with controls.
#Statistically significant (p,0.05) when
compared with HIV gp120 treated cells.
doi:10.1371/journal.pone.0028014.g005
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[44,48]; giving rise to soluble forms of gp120. On the surface of the
virus, the gp120 is known to exist in the form of trimers, and is also
reported as monomers, with the monomeric form being highly
accessible [43,49–52]. While the affinity constants of the trimeric
gp120 to hMR have not been determined; considering the high
affinity of monomeric gp120 to hMR, hMR could concentrate the
virus on the mucosal surface and may act as a local reservoir.
Given the fact that each virion would carry around 24 copies of
gp120 [53,54], accumulation of virus particles above a threshold
would possibly activate a range mechanisms pertaining to epi-
thelial cell damage and transcytosis to gain entry in to sub-
epithelial layers. It is also possible that the affinity of hMR to
trimeric gp120 may be higher than the monomeric form (used
herein) which may further potentiate accumulation of the virus in
the tract.
In vivo, mannosylated proteins and other ligands for hMR are
known to trigger a plethora of signaling cascades to elicit biological
effects [55]. In astrocytes, it has been demonstrated that under the
influence of HIV, hMR activates PI3-kinase signaling leading to
production of MMPs [20]. Indeed, an increase in MMPs has been
found in various HIV associated pathologies [56]. HIV signaling
would largely depend on exposed accessible gp120 at its surface,
which contains both trimeric and monomeric forms with the
monomeric form though less in quantity is highly accessible
[43,49–51]. To test if the binding of monomeric HIV gp120 to
hMR may induce the production of MMPs in vaginal epithelial
cells, we challenged the Vk2/E6E7 cells with increasing concen-
trations of gp120 and tested for MMP-2 and MMP-9 transcription
and their activities. A dose dependent increase in the mRNA
expression and activity of MMP-9 but not MMP-2 in response to
HIV gp120, was observed. The levels of TIMP-1, TIMP-2 and
TIMP-3 mRNA in gp120 treated and untreated cells were
identical (unpublished data). These results imply that HIV
gp120 induces MMP-9 production in vaginal epithelial cells.
Beyond hMR, the vaginal epithelial cells have other HIV binding
proteins like gp340 and syndecans [16,26]. To test if the induction
of MMP-9 by HIV gp120 in the epithelial cells is via hMR or
other HIV binding proteins, we tested the effects of an hMR
neutralizing antibody on gp120 mediated MMP-9 production.
The anti-hMR antibody completely abrogated the HIV gp120
mediated increase in MMP-9 production and the levels were
identical to untreated controls. These results indicate that the
effect of HIV gp120 on MMP-9 production is specifically via
hMR. It will be of interest to determine if the other gp120 binding
proteins like syndecans or gp340 also actuate signaling cascades
that culminate into activation of proteases. Furthermore, it would
be of interest to compare the effects of monomeric and trimeric
gp120 on hMR mediated protease production; and determine if
the upregulation in proteases observed herein in our study, is
further increased by trimeric gp120. These studies using trimeric
gp120 merit further investigation.
In the context of the vaginal epithelial layer, the observation
that HIV gp120 induces MMP production is pathologically
relevant. MMPs are proteolytic enzymes employing a range of
substrates like collagen, fibronectin etc. [56]. MMPs are also
known to degrade tight junction components, followed by dis-
ruption of the overall tight junction complex leading to increased
permeability [57–60]. Degradation of adherens junction compo-
nents by MMPs has also been reported [61,62]. The increased
production of MMP-9 in response to HIV gp120 would lead to
possible degradation of tight junction proteins, and the extracel-
lular matrix in the vaginal epithelium and the basement mem-
brane, thereby weakening its integrity and permitting entry of viral
particles. Supporting our hypothesis of vaginal epithelial barrier
leakiness, Nazli et al. [21] reported a decrease in expression of
junctional proteins with increased permeability of genital epithelial
cells, following HIV gp120 binding. These results together with
our observations that HIV gp120 is capable of inducing MMPs,
prompt us to hypothesize that HIV itself facilitates its initial entry,
by compromising the integrity of the host tissue, thereby gaining
access to the deeply embedded immune cells to obtain a per-
manent residency and replicative potential in the host. This
mechanism would gain further significance in women where the
epithelial layer integrity is already compromised due to physical
insults or infections; further activation of MMPs and/or loss of
junctional proteins by the virus would immediately make the
barrier extremely vulnerable to HIV entry. Not surprisingly the
incidence of HIV infection is known to be very high in women
with different causes of epithelial layer damage [2,6].
In conclusion, this study has identified hMR to be expressed in
vaginal epithelial cells and binds HIV gp120 with high affinity.
The presence of an HIV binding receptor in the vaginal epi-
thelium that would facilitate MMP production thereby weakening
the vaginal epithelial barrier, presents a potential new mechanism
for mucosal transmission of HIV. Further delineation of the
downstream events in the hMR pathway would lead to a more
detailed understanding of the early events in the mucosal
transmission of HIV. This would open up newer avenues in the
design of microbicides like hMR antagonists or MMP inhibitors to
block HIV in its tracks at the portal of entry.
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